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Introduction 
 
CRISPR-Cas9 can shift the ethics of gene therapy 
 
The discovery of the CRISPR system in many ways epitomizes the rewards of genuine 
scientific curiosity to understand natural phenomena. What turned out to be CRISPR was, at the 
time, nothing more than repeating patterns in the genome of bacteria and in this context 
presented no fame, money, or prestige. However, what was born out of the understanding for the 
mechanism that generated these repeating patterns is now responsible for a growing excitement 
in the scientific community and has become anything but humble. Unlike its origin.  
CRISPR, in its essence, is nothing more than a bacterial immune system that, when 
combined with the Cas9 enzyme, becomes a powerful and effective tool to edit genomes in 
eukaryotic cells. Since the genome is the fundamental blueprint of living organisms, harnessing 
this power presents the ability to alter very specific traits that seem to be limited only by our 
creative potential.  
Its use since 2012, when it was first developed into a gene editing tool, has had far 
reaching impacts on research, and is now finding its way into use on humans. Said uses have so 
far been limited to research on its medicinal use via gene therapy. Even though CRISPR-Cas9 
presents a tremendous upside by offering cures to genetic illnesses, there has been reluctance to 
adopt its use. This is because the use of CRISPR-Cas9 on humans brings up new questions of 
science and progress that are unprecedented: questions such as how to balance the risks and 
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benefits of CRISPR, or even to what extent should we use technology to modify life when such 
modifications are made possible.  
These questions represent matters that can have a profound effect throughout society and 
in life.  It is therefore imperative to realize that progress for the mere sake of progress is 
something that can lead to very dangerous outcomes and there must be regulation to prevent such 
outcomes from occurring. Because the use of CRISPR-Cas9 on humans falls into the realm of 
gene therapy, regulation of its use on human bodies has thankfully already been established the 
creation of gene therapy. The important nuance to this, however, is that these regulations are not 
“set in stone”.  
 This highlights an important trend in bioethics because it has become a means of 
regulating the social acceptability of newly emerging technological possibilities and implies that 
there is an underlying relationship between technology and society. Since the regulations on gene 
therapy stem from bioethics, the implications of this relationship are massive as it suggests that 
CRISPR-Cas9 possesses the agency required to incite change in the ethics/ regulatory framework 
of gene therapy. Further, as CRISPR-Cas9 gene editing advances by becoming increasingly 
accurate and cheap, it is also becoming increasingly apparent that it will cause a shift in the 
ethics of gene therapy. To explain how this occurs, I must first emphasize the impact of 
CRISPR-Cas9 on gene therapy and highlight specific points where it can change the ethics of it.  
When gene therapy was first postulated, it generated much excitement due to the 
possibilities for fighting many genetically linked illnesses. Unfortunately, success was elusive as 
gene therapy failed to live up to its initial expectations as it was demonstrated to be very 
expensive as well as dangerous. Not surprisingly, much of the excitement wore off. However, 
gene therapy continued to present an upside insofar that it gave way to the possibility of gene 
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editing, which was beginning to be fulfilled through the development of zinc finger nucleases 
(ZFN) and transcription activator-like effector nucleases (TALENs). While these technologies 
are still in use, the emergence of CRISPR-Cas9 presents a disruption in the use of gene therapy.  
By tracing the development of gene therapy research using CRISPR-Cas9 since 2012, I 
have observed a pattern of its increasing infringing upon the bios. If this pattern continues, the 
use of CRISPR-Cas9 for gene therapy will eventually collide with established ethics. This, in 
turn, will force their reevaluation. To suggest that this is the case, I will focus on two current 
restrictions that CRISPR-Cas9 is likely to have an impact on: the ban on germline manipulation 
and limits to the medicinal application of gene editing. 
This is mainly due to questions regarding the safety of using CRISPR-Cas9 since the 
long-term effects have yet to be fully evaluated, and some scientists have called for a 
moratorium. Interestingly, this response parallels that of the early use of DNA recombinase 
technology which has since grown considerably and is becoming increasingly normalized in 
society today. It is through this normalization where the shift in ethics regarding germline 
manipulation and accessibility can occur, driven by biopolitical forces that constitute both a will 
and a means for normalization. 
 This interaction provides the framework for my thesis, in which my aim is to suggest the 
bioethics of gene therapy will shift by the rise of CRISPR-Cas9 gene editing. To do so, I will 
explain how shifts in the bioethics of gene therapy are occurring through contemporary CRISPR-
Cas9 research. Further, this will be done by outlining the biopolitical forces driving shifts in 
bioethics and how they serve as a mechanism for shifting the ethics/regulations of contemporary 
gene therapy. I hope that it will serve to both highlight how far we have come, and, based on this 
trajectory, what can come next vis-à-vis the ethics of gene therapy and its use on humans.  
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  Chapter One: 
 
 
Contextualizing CRISPR-Cas9 in Gene Therapy 
 
 
Few discoveries can redefine our fundamental understanding of nature and change the 
course of humanity. When in 1868 a young Friedrich Miescher looked microscopically into 
the pus of discarded surgical bandages and discovered a new molecule (aptly named nuclein) 
(Dahm, 2008), little did he know that he was staring at such a discovery. Years later, nuclein’s 
capability was realized when Hershey and Chase confirmed that it (now known as DNA) was 
the carrier of genetic material and a year later the now famous Watson and Crick solved its 
structure with the aid of Rosalind Franklin and Maurice Wilkins. For the first time in human 
history, we could finally metaphorically stare into the eyes of God by understanding how we 
are created. What truly made this discovery change humanity however, is the development of 
technologies stemming from the understanding of DNA and its role in building proteins 
unique to every species. Doing so is allowing us to influence the very essence of that makes 
living organisms what they are through genetic modification.  
To understand this influence, one must first understand the background of genetic 
modification and its interaction with society. Genetic modification is nothing new. Despite a lack 
of understanding of genetics, humans have influenced the phenotypes of other organisms for 
around 32,000 years. In East Asia, wolves were selected to become more submissive which 
eventually led to the selection of certain traits to give us modern dog breeds (Wang, Guo-dong, 
et al., 2012). In ancient Mexico, kernels from particularly large and perhaps better tasting 
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teosinte grass were selectively planted, resulting in progressively larger teosinte which displayed 
more rows of kernel and eventually become known as maize (Doebley, John, et al., 1990).  
It would be thousands of years until Darwin’s The Origin of Species brought about an 
understanding of evolution and subsequently artificial selection. This understanding, alongside 
that of Gregor Mendel’s concept of heredity redefined our understanding of humanity’s place in 
nature. In other words, where previously our understanding of where organisms originated rested 
on creationist ideology, a paradigm shift occurred giving humanity a newfound agency as it now 
believed that it was a part of nature (Berra, 2008). With this newfound agency, research would 
shift to the dominant paradigm and proceed into what Kuhn called a “normal science” (Kuhn, 
2012). Within normal science said research was done and continues to be done through a puzzle-
solving framework that aims to further understand and explain heredity, leading to the discovery 
and further understanding of DNA’s role in heredity. 
 The process of furthering this understanding also allowed for the development of new 
technologies. In the early 1970’s, this development was manifested with the creation of direct 
DNA manipulation through genetic recombinant techniques. Its earliest use created the first 
transgenic organism by inserting antibiotic resistance genes into the plasmid of an E. coli 
bacterium (Cohen & Chang., 1973). The relative success of this work set the precedent for future 
genetic modification, however, despite the opportunities recombination technology presented, 
the environmental and public health risks were uncertain, hence society was hesitant to adopt its 
use.  An example of this is the use of SV 40, which was known to cause cancer in rodents and 
thus, there was the fear human cell cultures which underwent SV 40 recombination could break 
out and cause cancer (Berg, 2008). 
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Risks such as those posed by SV 40 as well as the fear of additional unknown risks led 
scientists to sound the alarm and called for a global moratorium on the use of DNA 
recombination. However, the moratorium was never implemented and instead the reservations of 
scientists led to a conference in 1975 held at Asilomar to set standards that had both public 
health and research interests in mind. This now famous conference set forth early standards and 
safety guidelines for work with recombinant DNA.  
Further, the decisions and guidelines laid out at the Asilomar conference also increased 
public interest in genetic modification, which has been attributed for kick starting the 
biotechnical industry (Wright, 1986) that increasingly sought out ways to apply genetic 
modification to medicine. Because of this push, gene therapy, which aims to replace or disrupt 
defective genes, was born in the early 1990’s. The first use of gene therapy was used to treat 
four-year old girl Ashanti DeSilva who suffered from ADA-SCID (Blaese., et al., 1995).  A few 
years later, cancer gene therapy was introduced (Trojan., et al. 1993), and new vectors were used 
to deliver genes (Abbott, 1992). This was cause for a lot of excitement as it opened a lot of 
treatment options for many previously incurable illnesses. For a short period during this time, it 
appeared as if a new paradigm4 in medicine was in order.  
Unfortunately, gene therapy did not live up its potential. Obtaining lasting effects was 
difficult, if not impossible in early trials, and the community quickly grew skeptical (Friedman, 
1996). Then, the 1999 gene therapy related death of Jesse Gelsinger signaled a warning sign to 
the American scientific community, which responded by suspending several trials. Further, in 
2003 this skepticism was additionally soured when reports from Paris announced that several 
																																								 																				
4	The	use	of	the	word	“paradigm”	in	this	case	is	does	not	apply	to	the	Kuhnian	definition	because	it	applies	strictly	
to	technology.	Rather,	here	it	is	used	to	show	that	beliefs	regarding	gene	therapy	as	an	application	to	medicine	
were	widespread.			
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gene-therapy patients developed leukemia, leading to one death. Despite subsequent reports of 
successful gene therapy, there remained a sense of doom around the issue and gene therapy was 
now at a dead end.  
Returning to the puzzle-solving framework described above, the new paradigm of gene 
therapy presented different ways of delivering genes. Where the first technology was focused on 
activating certain proteins that led to failures which the increased pessimism of gene therapy, 
technology progressed to enable the actual editing of genes themselves. This development has so 
far created technologies such as gene editing technologies such as ZFN and TALENs. However, 
the very recent development of CRISPR-Cas9 has/is creating a lot more excitement than the 
former due to its potential to edit genes much more effectively and cheaply. To understand why 
this is, and what makes CRISPR-Cas9 such a powerful gene editing tool, it is imperative to 
understand how the technology works. 
Despite often being viewed as a single entity, CRISPR-Cas9 is an interaction between the 
CRISPR loci and its Cas9 effector enzyme. Clustered regularly interspaced short palindromic 
repeats (more commonly referred to as CRISPRs) serve as an adaptive immune system for 
bacteria against infections (Mojica, et al., 2005). They are broken up into two different classes, 
class I contains multi-subunit effectors while class II contains single protein effectors. Within 
these classes are five different subtypes, CRISPR-Cas9’s being class II type II (Lander, 2016), 
due to differences in individual types, only the pathway of type II immunity is described below1.  
 
																																								 																				
1	It	is	interesting	to	note	that	there	are	many	different	types	of	CRISPRs,	however,	because	the	scientific	focus	lies	
largely	on	the	CRISPR-Cas9	mechanism	for	gene	editing	(as	opposed	to	working	with	other	CRISPR	systems)	
warrants	some	consideration	as	to	how	this	push	can	be	socially	constructed	through	actor	network	theory.		
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CRISPR immunity works in three different stages which work to break down invading DNA: 
 (1) acquisition, (2) crRNA processing, and (3) interference.  
1. Acquisition begins with the recognition of invading DNA (such as a bacteriophage) by 
the Cas1 and Cas2 enzymes, leading to the cleavage of a protospacer. The protospacer 
then is ligated to the direct repeat adjacent to the leader sequence and single strand 
extension repairs the CRISPR and duplicates the direct repeat.	The primary CRISPR 
transcript is cleaved by Cas genes to produce crRNAs (Swarts et al., 2012). 
 
2. crRNA processing in type II systems involves the use of trans-activating (tracr) RNA to 
form dsRNA, which is cleaved by Cas9 and RNaseIII.	Secondary trimming is then 
performed at either the 5’ or 3’ end which produces mature crRNAs. These mature 
crRNA associate with Cas proteins to form interference complexes. 
 
 
3. Interference is caused by the resulting complex (Cas9 + tracrRNA + crRNA) which 
locates the DNA sequences that match the spacer sequence and binds to the target site 
with the help of PAM. Once Cas9 binds to a target site with a match between the crRNA 
and the target DNA, it cleaves the DNA three bases upstream of the PAM site (Lander., 
2016). 
The image below2 both illustrates and summarizes the class II, type II CRISPR-Cas9 system3.  
																																								 																				
2	This	image	was	originally	published	in	Vol.	164	p.	19	of	Cell	in	the	article	“The	Heroes	of	CRISPR”	by	Eric	S.	Lander	
3	From	this	image,	it	is	important	to	notice	that	in	the	last	step,	the	cleavage	site	creates	two	blunt	ends	because	
this	gap	can	be	manipulated	to	be	filled	by	an	artificial	sequence,	which	gives	CRISPR-Cas9	the	ability	to	edit	genes	
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The use of the CRISPR associated (Cas9) protein is critical in type II CRISPR immunity as it 
is the only known effector for this type. This is due to its unique structure which allows it to 
locate and cleave target DNA with high accuracy and efficiency. Its structure is broken up into 
six domains: REC I, REC II (role not well understood), the Bridge Helix, the PAM interacting 
domain, HNH and RUVC. REC I is responsible for binding to the guide sequence, while the 
bridge helix initiates cleavage activity upon binding on the it. The PAM interacting domain 
confers PAM specificity, making it responsible for initiating binding to target DNA. The HNH 
and RUVC domains cut the single-stranded DNA. (Nishimasu et al. 2014).  
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What gives CRISPR-Cas9 the ability to edit genes relies on the fact that the Cas9 can be 
activated with an artificial guide sequence which targets a specific area. This activates the second 
stage of the CRISPR system in which the Cas9 enzyme locates the matching protospacer 
adjacent motif (PAM) sequence and cleaves it which leaves a gap in the genome. This gap can 
then be filled by an artificial repair template that can be tailored to suit a specific need (such as 
fixing an SNP) by taking advantage of the cell’s natural HDR process. Since this can be done on 
purpose and any desired sequence can be inserted into the target area, this technology gives us 
the power to edit virtually any genome. Additionally, this replacement becomes part of a cells 
genetic material, it is permanent. Therefore, it will pass into its daughter cells which gives 
CRISPR-Cas9 the ability to be used in gene therapy as a means of correcting genetic errors as 
well as preventing them from being passed on.  
Nevertheless, there is an important caveat. CRISPR-Cas9 technology is by no means perfect, 
which can result in poor editing rates. Yet, since the discovery of CRISPR-Cas9 as a gene editing 
tool, these rates have decreased based on new advances. Said advances mainly come from the 
development of new ways to deliver the essential CRISPR machinery, namely through the recent 
use of ribonucleotide particles (RNP) which have been found to enable the highest editing 
efficiencies thus far. (Liang, X., et al., 2015) Further, the development of synthetic guide RNA 
(sgRNA) has added to this efficiency when combined with RNPs as researchers have 
consistently achieved a 90% efficiency.  
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The following image4 helps contextualize the extent of the advances made in using CRISPR-
Cas9 technology:   
 
As can be observed in the chart, the comparison between the different technologies and their 
corresponding efficiencies shows that recent technological developments are not only more 
efficient in terms of gene editing, but also increase productivity in the experimental process 
itself. This is done by reducing the time and cost required to use CRISPR-Cas9. In addition, the 
simplicity of the type II CRISPR system that I have described above gives CRISPR-Cas9 gene 
editing a lot of potential in the field of gene therapy because of how easily it can be used.  
If this is the case, and if anything, the increased involvement from the private sector (Berg, 
2008) strengthens the argument that it will, then the use of CRISPR-Cas9 for gene therapy on 
																																								 																				
4	Adapted	from	CRISPR	101	by	the	Synthego	Corporation	available	for	download	online	at:		
http://powered.synthego.com/crispr-101	
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humans will become more prevalent. This is because the potential monetary and medicinal 
benefits will lead to further development, which will make the technology safe for human use. 
Doing so will likely signal a new era in molecular biology and gene therapy as CRISPR-Cas9 
technologies will continue to be used and become increasingly normalized in society.  
Without a doubt, this new era in molecular biology will run into a plethora of ethical issues. 
However, ethics are a social construct and are therefore malleable. Naturally, this begs the 
question of how CRISPR-Cas9 can become normalized in contemporary society and 
subsequently affect the contemporary ethics of human germline manipulation. The answers to 
this question will be addressed throughout the remainder of this thesis.  
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Chapter Two: 
 
 The contemporary ethical frameworks behind gene therapy and the bio-political 
background for their disruption via CRISPR-Cas9 technology 
 
 
The age-old question: “Just because we can, should we?” embodies the thoughts which 
can naturally arise when one thinks of gene therapy. After all, the ability to manipulate one’s 
genome contravenes the boundary between man and nature. Doing so makes it more difficult to 
know what exactly is natural and how it can be distinguished from what is artificial. After all, 
these boundaries remained unquestioned since they laid well beyond our capabilities. However, 
this has since changed with the increase in biotechnology and therefore these existential 
questions are becoming increasingly relevant as technology advances and further disrupts this 
boundary.  
These questions began to arise in the 1970’s, when DNA recombination became available. 
According to Thomas Lemke, it became necessary for society to respond by regulating which 
processes were acceptable and under what conditions in addition to clarifying what kind of 
research would be prohibited (Lemke, 2011, p.26). This act is epitomized by the Asilomar 
Conference, where scientists, journalists, and policy makers got together to decide on such 
regulation. Among these, I am highlighting both of the following recommendations because they 
highlight the balance between both research and public health safety that was the key message 
from Asilomar5:    
																																								 																				
2	To	see	the	complete	guidelines	from	the	Asilomar	Conference,	please	see:	
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• Containment should be made an essential consideration in the experimental design 
and should match the estimated risk as closely as possible. 
• Government oversight is recommended until the technology is deemed safe  
By balancing the interests of both public safety and research, the Asilomar Conference also 
set an important precedent about how a proper response to new scientific knowledge was to 
develop guidelines that governed how to regulate it (Berg & Singer, 1995).  
The increased public engagement from the conference also had a side effect by bringing 
about private interest in genetic engineering and escalated the amount of progress made in the 
field (Berg, 2008). These advancements only further infringed upon the boundary as 
developments in gene therapy began to take place in the late 1980’s. Hence, the regulations 
Asilomar established only served as a Band-Aid because gene therapy raised a new range of 
ethical concerns due to the use of genetic modification on humans as opposed to non-human 
organisms.  
Of primary concern were the issues of the safety of the patient as well as the accessibility of 
gene therapy with regards to who could use it/ what should be treated. Thus, a second conference 
was held in 1990, this time focused on the ethics and human values regarding genetic screening 
and therapy. This conference produced the Declaration of Inuyama6 which established 
																																								 																																							 																																							 																																							 																																			
Berg,	P.,	Baltimore,	D.,	Brenner,	S.,	Roblin,	R.	O.,	&	Singer,	M.	F.	(1975).	Asilomar	conference	on	 	 	 	
recombinant	DNA	molecules.	Science,	188(4192),	991-994.	
	
6	The	full	text	for	the	Declaration	of	Inuyama	is	available	in	appendix	A	and	was	obtained	online	from	The	Council			
for	International	Organizations	of	Medical	Sciences	(CIOMS),	in	official	association	with	the	World	Health	
Organization	(WHO).	A	copy	is	also	available	online	at:	
http://www.cioms.ch/publications/guidelines/1990_texts_of_guidelines.htm	
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regulations and gave recommendations for the future use of gene therapy.7 While the creation of 
this declaration was an inherently political act, the considerations it placed on the regulation of 
gene therapy are naturally situated closely to the concerns of bioethics. This is simply because 
the act of creating such regulation on “the social acceptability of what is technologically 
possible” (Lemke p.26), touches on essence of what ethics are: moral principles that govern a 
group’s behavior. 
 With this in mind, it is imperative to understand that regulation regarding the use of gene 
therapy then simply becomes the product of several ethical frameworks that are largely informed 
by sociological thought. Said frameworks are prevalent throughout the declaration of Inuyama 
and consist of utilitarianism, Kantianism and liberalism.  
 
Utilitarian and Kantian Ethics 
Germline gene therapy would specifically target human reproductive cells. As such, any 
modification made to these cells would be passed down to future generations. This would allow 
the correction of harmful genetic variations that have been passed down throughout human 
existence and spare future generations from the disease (Anderson, 1989). However, section VI 
of the Declaration of Inuyama states “The modification of human germ cells for therapeutic or 
preventive purposes would be technically much more difficult than that of somatic cells and is 
not at present in prospect. Such therapy might, however, be the only means of treating certain 
conditions, so continued discussion of both its technical and its ethical aspects is essential. 
																																								 																				
7	While	there	have	been	other	similar	conferences	since	then	(i.e.	the	2016	Summit	of	Human	Gene	Editing),	they	
have	largely	reinforced	the	regulations	established	by	Inuyama	which	makes	Inuyama	central	to	discussions	on	the	
ethics	of	gene	therapy.	
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Before germ-line therapy is undertaken, its safety must be very well established, since changes in 
germ cells would affect the descendants of patients” 8. Hence, germline modifications are 
currently banned9. As such, any U.S. public funding into this research is not allowed10 which has 
manifested itself through an NIH prohibition on research using gene-editing technologies in the 
human germline citing “ethical concerns” (Collins, 2015). 
From the text, it is clear that the future use of germline modification is feasible, however, 
ultimately the safety issues are of concern which led to the ban on its use. This is the clear work 
of both utilitarian and Kantian ethics; since the prohibition is a product of both more difficult 
techniques which would require more resources (and hence lack utility) as well as a moral (and 
therefore Kantian) opposition to subject future generations to potential danger.  
In terms of utilitarian ethics, which focuses on maximizing utility, the amount of research 
required to produce technology that enabled safe germline manipulation before the advent of 
CRISPR-Cas9 would have been very costly compared to the limited number of lives that could 
be saved. Therefore, allocating funds to create such techniques would greatly violate a 
foundation on utility. This is due to two factors, firstly, gene therapy techniques are mainly 
focused on treating illnesses that are caused by a single defective gene, which limits the 
population that it can treat. Secondly, such funding could better serve people suffering from 
genetic disease if invested in another way such as in-vitro fertilization (IVF) or genetic screening 
as this could also limit the spread of said disease to future generations.  
																																								 																				
8				Refer	to	appendix	A		
9				For	a	list	(last	updated	August	2014)	of	countries	banning	germline	editing,	please	see:	
	Ishii,	T.	(2014).	Potential	impact	of	human	mitochondrial	replacement	on	global	policy	regarding	germline	
	 	 	gene	modification.	Reproductive	biomedicine	online,	29(2),	150-155.	 	
10				Part	§46.124	of	the	United	States	Code	of	Federal	Regulations	
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It is interesting to note that while prohibiting germline gene therapy under current 
conditions due to “ethical concerns” (Collins, 2015), section VI11 also makes a rather vague case 
to continue the technical discussions regarding future use. This presents an oxymoron since 
research on the subject matter cannot receive funding from the U.S government, and seeking 
outside funding was difficult due to the similar standards set by the Declaration of Helsinki (Riis, 
P. 1977), hence this limited any possible (and very expensive) research to be funded by entirely 
private sources. Therefore, official progress in germline gene therapy under these restrictions 
could not be made. However, this does not account for alternative technologies that can become 
normalized overtime and modified to fit this purpose, as is potentially the case for CRISPR-
Cas9. In this case, utilitarian ethics can very well shift as this use of technology suddenly 
presents greater utility than current alternatives.  
 Ultimately, the safety issue presented in section VI of the Declaration of Inuyama is 
clearly underscored based on the premise that the impact of germline manipulation is carried 
forward through generations, as can potential errors. Thus, when this policy was made, those in 
charge placed a heavy weight on Kantian ethics, since this ethical framework accounts for the 
basis of morality through the categorical imperative. In other words, in Kantian ethics, all 
rational beings (i.e. humans) can never be treated as means to an end, and as such it is morally 
obligatory that they be treated as an end (Kant, 1775). 
 In the case of medical ethics (in which gene therapy falls under) this morality is rooted 
upon the premise that all humans should have the right to dignity and respect. Applied further, 
this ethical framework makes it imperative that patients (such as those undergoing gene therapy) 
																																								 																				
11				Refer	to	appendix	A		
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are treated as treated as rational and moral people (an end) and thus should never be used to the 
benefit of society (a mean) (Sugarman & Sulmasy, 2010).  
This moral theory serves as the basis for the safety clause in the Declaration of Inuyama 
by emphasizing that those who undergo gene therapy be treated as an end. Because germline 
manipulation has not been well established and thus its impact on both the patient and future 
generations is unknown, it cannot possibly be an end. Instead, it would lead to disregard of 
patient and their offspring’s safety in the name of progress, which is in violation of Kantian 
ethics.  
  
Liberal Ethics 
 Aside from the prohibition on germline manipulation in gene therapy, another key ruling 
is found in the Declaration of Inuyama is the accessibility of gene therapy. This is done by 
establishing regulation as to who can be treated. Section V affirms that “… Interventions should 
be limited to conditions that cause significant disability and not employed merely to enhance or 
suppress cosmetic, behavioral or cognitive characteristics unrelated to any recognized human 
disease”. By limiting use to treat only those who suffer from a genetic disease, this clause 
essentially deters any potential misuse related to enhancement. While the reasons behind this are 
not explicit in the declaration, since it was written there have been many ethical arguments made 
about genetic enhancement12.  
These arguments generally boil down to the viability of genetic enhancement as well as 
its social impact. For the former, the viability is mainly the result of the limitations of being able 
																																								 																				
12	A	summary	of	these	arguments	can	be	found	in:	
	Baylis,	F.,	&	Robert,	J.	S.	(2004).	The	inevitability	of	genetic	enhancement	technologies.	Bioethics,	18(1),	1-26.	
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to edit more than a few genes at a time and thus genetic enhancement would be difficult given 
that more than a few genes would need to be altered13.  For the latter, the social impact of 
enhancement technology could freeze upward mobility within a nation (Mehlman, 1999) and 
globally further divide the gap between rich and poor countries. 
The reasoning for this argument is that gene therapy can be very costly as is evidenced by 
the staggering record price of Glybera, which was marketed at a price of $1 million dollars to 
treat lipoprotein lipase deficiency (Morrison, 2015). Naturally, these high costs marginalize the 
poor and subsequently wealthier nations are better equipped to use gene therapy on their citizens, 
which could ostracize citizens in poorer countries. This issue is elegantly summarized by David 
Shenk in a 1997 essay in Harper Magazine when he pronounces that “…the social advantage 
that wealthy societies currently maintain could be converted into a genetic advantage. And the 
already wide gap between wealthy and poor nations could widen further and further with each 
generation until all common heritage is gone. A severed humanity could very well be the 
ultimate legacy of unfettered global capitalism” (Shenk, 1997). While Shenk’s article was 
written years after the Declaration of Inuyama, the issues were clearly considered. This is 
evidenced by Sec. V which bans enhancement as well as Sec. VIII which stresses that the needs 
of developing countries be considered so they obtain a fair share of benefits (from the human 
genome project) such as gene therapy. 
Given this context, the framers of the Declaration of Inuyama certainly placed a high 
value on the ethical principle of liberalism by pushing for equality since equality of access is an 
ideal. After all, the intention of limiting the influence of money on gene therapy provides more 
opportunity to everybody to receive treatment that is necessary. Furthermore, by emphasizing 
																																								 																				
13		See	utilitarian	ethics	section		
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liberal ethics, the Declaration of Inuyama fosters the spirit of globalization. This underscores the 
message that gene therapy is truly a global pursuit and as such, such technology could have an 
impact on everybody’s life which is why access is important.   
 
The Declaration of Inuyama 
By looking at the situation leading to the Declaration of Inuyama itself, it must be 
realized that this was both a political act as well as a response to concerns that had never come 
up before. This suggests that certain ethical considerations had to be balanced over others, and 
that the people who formed the Declaration of Inuyama are the sole decision makers that 
weighed these issues to establish the ethics of gene therapy. In this case, there were 102 
participants from 24 countries representing all continents. Their fields of expertise ranged from 
biomedical science to sociology, law, social policy, philosophy. They also brought in relevant 
experience in hospital and public health medicine, universities and private industry, and the 
executive and legislative branches of government. Because they came about a broad agreement, 
it is a safe assumption that their views embody the general perspectives of the world. 
Based on these demographics, the feedback was given by a relatively diverse range of 
specialists in their fields as well as geographic makeup. Given this, the ethical frameworks which 
were given priority and mentioned above come to no surprise. What is worth noting about this 
however, is that while the World Health organization and the United Nations sponsored the 
event, there is no official enforcement agency. Hence, the Declaration of Inuyama is merely an 
agreement from those present to uphold these standards. As such, each entity is tasked with 
following the declaration based on their own independent agencies such as the internal review 
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board (IRB) or the FDA in the United States. This leaves room for individual interpretation, 
which can influence how countries regulate future technology. 
 Further, the Declaration of Inuyama was more than just politics. According to Thomas 
Lemke, interpreting such an act as traditional politics in incomplete, since biotechnology both 
encompasses the political subject and presumes that the political sphere remains untouched by 
growing technological possibilities (Lemke, 2011, p.30). Because these growing technological 
possibilities can at times further interrupt the boundary between man and nature, reevaluating 
previous regulations is practical based upon newfound understandings.  
 The development of CRISPR-Cas9 into a gene editing tool (Jinek et al, 2012), presents 
such a case. With the potential power for man to change the blueprint of cells, CRISPR-Cas9 is 
again forcing us to reestablish this border. In regards to gene therapy, this technology is 
appearing to become more accurate (and therefore safer) in successfully editing genes with the 
advent of synthetic guide RNA (Synthego, 2015). Surely if this progress continues, then we will 
be forced to revisit Inuyama since many of the regulations are premised by the lack of safe 
technology. After all, the improved safety of CRISPR-Cas9 has the potential to make its 
adaptation into gene therapy ethically feasible as noted above.  
The impact of CRISPR-Cas9 would certainly force an update on the regulations of gene 
therapy if it were to be implemented. Ethics are ultimately just social constructs, and because the 
regulations behind gene therapy are based on them, any change could have a profound change on 
regulation.  However, this does not mean that the Declaration of Inuyama should become 
obsolete since the balance of ethical perspectives established by it can be used to inform future 
policy by serving as precedents. If this is the case, then the use of CRISPR-Cas9 to modify the 
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germline can occur given both the lack of universal enforcement of regulations as well as by 
giving rise to a new interpretation of these ethical frameworks.  
Because the boundary between man and nature is consistently shifting and needing to be 
reestablished, the altering of these regulations is not only possible but also justifiable. As such, in 
accordance with current ethical standards, any application of this technology should be restricted 
to somatic cells, at least at first. Yet if we refer to the precedents set forth by both the Declaration 
of Inuyama and the International Summit on Human Gene Editing, there is a very real possibility 
of CRISPR-Cas9 being used to edit the human germline. After all this technology is not only the 
cheapest and most effective way to edit the genome, it is also becoming increasingly safer and 
there is a large push for more research; both of the latter suggesting that CRISPR-Cas9 follows 
up on the preceding standards which allow for germline manipulation. This again leads us to the 
question: Just because we can, should we? 
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Chapter Three: 
The will and the means: How can the normalization of CRISPR-Cas9 undermine 
current regulation in gene therapy? 
  
What does a stone cutting tool have in common with a high-pressure water jet cutter? The 
obvious answer is that they can both cut an object; but other than that, there are little similarities 
in terms of accuracy, precision, time, and even what materials can be cut. When we look a little 
deeper, however, we see that both are constructed based on our fundamental understanding of 
nature in the context of history. Hence, when I paraphrase Martin Heidegger’s The Question 
Concerning Technology by saying that technology is merely the application of science 
(Heidegger, 1977), this should come to no surprise. Continuing this line of logic, since science is 
a social construct, then the technology it produces is socially constructed as well.  
 Technology is not concrete and therefore is subject to change or even disappear based on 
how society views its application. Thus, throughout time, the technologies that tend to stick have 
become a part of a societal norm; suggesting that there is a certain political aspect to its 
application for it to be normalized. Returning to the cutting tool example, assuming the stone 
cutting tool was an early predecessor to the many modern cutting tools (such as the water jet), 
how did this technology evolve so much?  The answer is that it likely was a product of a 
fundamental need in society to accurately split something, and because the tool could fulfill said 
role, its application was normalized, leading to its continued advancement. This illustrates what 
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Langdon Winner argues, that it is not the tool itself which is an object of politics, but rather its 
use and application (Winner, 1980).  
The emergence of CRISPR-Cas9 gene editing technology as well as its potential for use 
in gene therapy falls well into this political framework. After all, the use of this technology must 
be able to fall in line with established societal standards so that it can become normalized. 
However, given the unique aspect CRISPR-Cas9 has as a biotechnology which has a direct 
impact on life, it also falls under the special realm of biopolitics. When life itself becomes 
politicized, the consequences are felt to the very core as the foundations, tools and goals of 
political action can shift (Lemke, 2011). Because of a shift in political action, bioethics, which 
are closely related to the changing biopolitics (Lemke, 2011, p. 26) can change as well. Herein 
lies the biggest issue and leads back to the question asked in chapter two: just because something 
is possible does not necessarily make it the right thing to do.  
Since biopolitics is inherently always changing based on new technologies that redefine 
the boundary between nature and man, it is entirely feasible that the ethical foundations which 
inform biopolitics can shift. For this to occur, however, the applications of this technology must 
become normalized; serving as the means to shift current regulations in gene therapy cited in 
chapter two. All that is needed for this to occur is tied to the concept of normalization which 
serves as a means for change while naturally being pushed forward with a driving force (i.e. the 
will)14.  
																																								 																				
14	The	concept	of	normalization	occurs	in	two	forms	in	sociological	theory.	For	the	purposes	of	this	thesis,	
normalization	refers	to	“normalization	process	theory”	which	is	a	framework	for	understanding	the	social	
processes	by	which	innovations	such	as	technology	become	routinely	incorporated	in	everyday	work	(May,	C.,	et	
al.,	2008).		This	is	not	to	be	confused	with	Foucault’s	use	of	normalization	which	appears	his	book	Discipline	and	
Punish	as	in	this	case	normalization	happens	within	the	individual	as	an	idealized	norm	of	conduct.			
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The will to normalize the use of CRISPR-Cas9 in gene therapy is best explained by using 
Michael Foucault’s concept of biopower.  In his book, The History of Sexuality: An 
Introduction” he describes biopower as "an explosion of numerous and diverse techniques for 
achieving the subjugations of bodies and the control of populations" (Foucault, 1976, p. 140). 
Simply stated, bio-power is the control over each individual’s body, which, when combined, 
come together to create the people’s body.  Through this, the people’s body behaves as a 
unanimous force rather than many different actors behaving in their best interest.  
Foucault advances on his assertion that bio-power and the state are intertwined as he 
mentions that the well-being of the people relates to governmental concerns of fostering the life 
of the population through anatomo-politics of the human body. It does so through regulatory 
controls of the body (such as birth, death and healthcare) through biopolitics of the population 
(Foucault, 1976, p.139).  
While one might believe that fostering life is a basic human right and thus the state 
doesn’t play a part in the bio-power dynamic, it is only a right because it is within the interest of 
the state (Arendt, 1973). This is because being able to maintain a healthy population is an 
integral feature and essential to the workings of the modern state and capitalism. Hence, it can be 
understood that the regulatory frameworks regarding the body are set by the state are with the 
sole intent of to "make live and let die” (Foucault, 1976, pp.136-161) and are therefore an 
exercise of power in the service of maximizing life. 
It is precisely this state incentive to grow in power by having healthier subjects that 
makes a strong argument for its motivation to pursue the use of CRISPR-Cas9 in humans via 
gene therapy. After all, CRISPR-Cas9 can not only edit the human genome, but it is doing it with 
increasing precision and cost effectiveness which put it at a distinct advantage over other gene 
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editing technologies like ZFN (expensive) and TALENS (inefficient). When this trait is 
combined with CRISPR-Cas9’s potential to cure many genetic and some nongenetic illnesses 
(i.e. retroviral diseases), it could not only save lives, but also extend the lives of many people and 
increase their quality of life. This in turn would make the state more powerful by harnessing a 
larger, healthier, and longer lasting workforce that can increase its productivity. 
While any significant use of CRISPR-Cas9 remains to be seen on humans, the driving 
forces for it are very real which give credence to the theoretical framework I established above. 
One example of this is the current competition between the United States and China. These two 
countries have invested the most in CRISPR-Cas9 research as getting gene edited cells into 
clinics across the world gives them more power over the other. Since CRISPR-Cas9 was 
developed as a gene editing technology, both countries have made substantial progress. 
However, this rivalry escalated in 2016, China was the first to test CRISPR-Cas9 on humans and 
sparked talks about “biomedical duel” on the progress of CRISPR-Cas9 gene editing 
(Cyranowski, 2016). Since then, both countries have continued to outline protocols for new gene 
therapies involving humans (such as new treatments for leukemia and other forms of cancer) at a 
rapid pace, suggesting that there is, in fact, a force pushing this research. 
It is important that I emphasize that biopower need not be purely driven by the state. 
Rather, the state can use its sovereign power (i.e. through regulations and/or funding) as a 
driving force in favor of CRISPR-Cas9 in the biotech industry. This, in turn, can increase the 
state’s biopower since the products of the biotech industry are subject to its regulation. This 
relationship is outlined in The Rise of the Ethical License which asserts that patents can be used 
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to manipulate the applications of technologies like CRISPR-Cas9 (Guerrini, 2017)15. In other 
words, government patents/ licensing can stimulate the market by incentivizing CRISR-Cas9 
research through the possibility of future profit and as such the government can use the biotech 
industry to gain further biopower.  
The stimulation of the market for CRISPR-Cas9 has resulted in its commercial 
proliferation such an incredible rate that Scientific American has called it “a genetic gold rush”. 
This is certainly not a hyperbole as pushes by the biotech industry to use CRISPR-Cas9 is 
leading to deals worth (in some cases) billions of dollars (Megget, 2016). To highlight how 
highly CRISPR-Cas9 is being sought after for its potential monetary benefit, a patent debate at 
the very heart of the CRISPR-Cas9 community is under way over who owns the technology as 
intellectual property (Starling, 2017)16. 
 Further, this competition both between institutions, the industry, and the state suggests 
that CRISPR-Cas9 is serving as a driving force because of the great financial opportunity it 
presents as well as the greater potential to increase biopower. It is this driving force that lends the 
potential to accelerate the progression of CRISPR-Cas9 research and its subsequent 
implementation on humans. However, returning to the fact that this technology deals with life 
itself, the driving forces advocating for the use of CRISPR-Cas9 in gene therapy are limited by 
restrictions predominantly related to its ethical use.  
																																								 																				
15	While	in	this	article	the	authors	specifically	argue	that	issuing	patents	can	be	used	to	restrict	controversial	
applications,	any	state	decision	regarding	restrictions	is	a	form	of	control	and	hence	why	the	biotech	industry	
serves	as	a	means	for	state	biopower.		
16	The	ongoing	patent	debate	is	between	UC	Berkeley	and	the	Harvard	Broad	Institute	in	the	case:	The	Broad	
Institute,	Inc.	v.	The	Regents	of	the	Univ.	of	California.	Declaration	of	Interference	No.	106,048	(2016).		On	February	
15,	2017,	patent	judges	ruled	in	favor	of	The	Broad	Institute	saying	that	the	patent	claims	did	not	interfere	with	
each	other.	This	decision,	however,	has	since	been	appealed	by	UC	Berkeley	through	the	U.S.	Court	of	Appeals	for	
the	Federal	Circuit.	Hence,	the	patent	debate	remains	open.		
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Throughout contemporary society, the normalization of using CRISPR-Cas9 in humans is 
already occurring, setting the stage for its use in gene therapy, and, following this trajectory, 
transcending current regulations. This process is loosely modelled after Georgio Agamben’s 
notion of bare life and the role it plays in normalizing biopolitical technologies (such as 
CRISPR-Cas9). While developing the notion of bare life, Agamben derives the distinction 
between the mere biological existence (Zoë) and the ethical being through political life (Bios) 
from both Aristotle and Hannah Arendt. Agamben then builds on this when he introduces his 
own interpretation in Homo sacer: sovereign power and bare life where he draws on the Roman 
figure of law to question the nature of law and power. He does this by posing the Homo sacer, 
who is manifested by an expelled man who can be killed with impunity but is unworthy of either 
juridical punishment or religious sacrifice. Thus, the Homo Sacer is merely a figure exposed to 
murderous violence that also has no political significance which Agamben poses as a 
representation of bare life (Agamben & Heller-Roazen, 1998. pp.12-44). 
Agamben applies this concept in his essay, No to Biopolitical Tattooing, where he 
exemplifies that anyone coming to America must get their fingerprints on file, as they are bare 
life since they are not American citizens by law. This process then becomes more normalized as 
more and more immigrants are fingerprinted to the point where the process of recording finger 
prints becomes more bio-politically acceptable to the point where people can use finger printing 
voluntarily to unlock their phone.  
 However, modernity has led to the implementation of other means of exploiting the Zoë 
and therefore expanding it to a new threshold and “could well be the precursor to what we will 
be asked to accept later as the normal… in the gears and mechanisms of the state” (Agamben & 
Murray, 2008 p.202). This allows the sovereign to legally control the Bios through the Zoë by 
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attempting to normalize borderline concepts. Once this normalization occurs, the restrictions 
previously held together by politics centered around ethics can be reduced by becoming more 
bio-politically acceptable. This is where the link between CRISPR-Cas9 use on humans and 
Agamben’s notion of bare life come full circle as modern biopolitical technologies are being 
normalized through the implementation on humans with varying levels of Bios (or Zoë 
depending on how one looks at it).  
In humans, the simplest level of bare body comes from the most basic unit of life: the 
cell, or rather the somatic cell for clarification. After all, assuming consent has been granted by 
the owner, the cell does not possess any level of political will. Rather, any political/ ethical 
implication on cell research is granted by the people who own the cell line.  Because of this 
absolute absence of political will, naturally, the first application of CRISPR-Cas9 in human 
genome editing was on the human somatic cell line 293FT, which was used to suggest that 
CRISPR-Cas9 can be used to edit eukaryotic mammalian cells (Cong, L. et al., 2013).  
According to the authors, while the accuracy and efficiency of CRISPR-Cas9 was not perfect, 
improvements can be made regarding different Cas9 enzymes and PAM requirements. With this, 
the stage was set for further use.  
The scientific community greeted this paper with open arms and soon after CRISPR-Cas9 
gene editing was integrated to target diseases in mice, serving as a precursor to gene therapy in 
humans. This progress is perhaps best epitomized by the December 2013 study that successfully 
cured mouse cataracts by editing the Crygc gene (Wu, Y., et al., 2013). While admittedly the 
early use of this technique was not exclusive to human cells, the same principal applies due to 
the lack of bios lab mice possess.  
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Furthermore, the general acceptance of this application on human cells and other species 
lacking bios served to normalize this early potential for CRISPR-Cas9 use in gene therapy. 
Through said normalization researchers were able to continue to develop this paradigm by 
further pushing studies into areas of added relevance to gene therapy. For example, in an August 
2014 study, the HIV-1 was successfully removed gene from the human genome by using human 
cell lines and the researchers referenced its potential future applications of this research 
explicitly as a form of gene therapy (Hu, W., et al., 2014).  
While the use of CRISPR-Cas9 on human somatic cells was easily normalized and 
ethically justified based on its exclusive use on the Zoe, its application as a gene therapy 
eventually must infringe on the bios to serve as an instrument of biopower. In April of 2015, this 
breach occurred when researchers from Sun Yat-sen University used CRISPR-Cas9 to modify 
the gene responsible for β-thalassemia, a potentially fatal blood disorder (Liang, Puping, et al, 
2015). While the results were largely unsuccessful, their choice to use non-viable human 
embryos led to controversy as scientists and researchers argued that it violated ethical concerns. 
While, these concerns were mainly related to the potential for germline edits (Cyranowski & 
Reardon, 2015), their off-target mutations are largely to blame because this was not a” safe” 
procedure.  
Clearly the reaction from the use of non-viable embryos versus cells is indicative that the 
process infringed upon what some consider to be ethical. This is a product of the embryo, 
regardless of whether it is non-viable, having more bios than a cell. After all, the bios is assigned 
by the sovereign and the fact that a human embryo more closely resembles a human than a cell or 
another species has historically given it more agency. Furthermore, because of this experiment, a 
conference held at the National Academy of Sciences in December of that year was much like 
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that of Asilomar and Inuyama in that it called to establish ethical regulations, this time governing 
CRISPR-Cas9 research on humans. Similarly, it also appears that this conference was inevitable 
as the advent of CRISPR technology once again infringed upon our place in nature, the study on 
non-viable embryos was the mere catalyst.  
Much like Inuyama, the 2015 conference aptly named the International Summit on 
Human Gene Editing ruled in favor of many regulations paralleling those of Inuyama, most 
importantly that the use of germline editing was irresponsible given the safety concerns. (Travis, 
2015). Ironically enough, around the time the summit was held, the wrench in the equation was 
preparing to be thrown only a few hundred miles north of Washington D.C. 
In early December 2015, Feng Zhang re-engineered the Cas9 enzyme into the S. 
pyogenes Cas9 enzyme (eSpCas9) with dramatic results as “off-target editing” was reduced to 
undetectable levels in the specific cases examined (Slaymaker, I., et al., 2016). Because of the 
enhanced accuracy of the eSpCas9 enzyme, the safety issues that were the essence of the 
International Summit on Human Gene Editing were largely undermined. This has opened the 
door for many more potential uses of gene therapy.  
However, the technology has not been fully normalized yet even despite the added safety. 
This largely has played a role in the decision to approve human trials using this modified 
CRISPR-Cas9 on patients with leukemia. The experiment, unfortunately, is merely a trial to 
assess the safety of these techniques on humans (Reardon, 2016). By using terminally ill 
patients, the framework for normalizing this technology is further suggested, since it is a step 
forward from working on the pure Zoë of cells, but the patients still lack a full political will since 
they have few choices besides this treatment.  
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If the studies planned for 2017 and beyond are successful, then this pattern of 
normalization could soon continue to those that have increasing political will. The next step 
would likely be to use CRISPR to cure genetic forms of blindness, namely retinis pigmentosa 
(Suzuki, K., et al., 2016). Here, again the same pattern of increasing infringement upon the bios 
can be observed, as one has increasing agency to decide whether they want they to partake in 
gene therapy. 
  If this pattern continues, then it is entirely possible that CRISPR-Cas9 can become so 
normalized in society that it becomes part of our everyday lives, much like Agamben’s example 
with finger printing. Doing so, would require a massive shift in regulation, nevertheless. 
Assuming Lemke is correct that the regulation of biotechnology is the product of politics based 
on bioethics (Lemke, 2011, p.26), the increasing ability of CRISPR-Cas9 to both respond to 
ethical concerns as well as shift the boundary between man and nature clearly give it the 
potential to undermine current gene therapy regulation. When this is coupled with a strong drive 
from biopower as well as the means to be normalized, this potential can be fulfilled. With this in 
mind, it is of the essence to plan for the possibility of a shift in bioethics which will be elaborated 
on in the next chapter.  
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Chapter Four: 
 
How CRISPR-Cas9 can shift the ethics of gene therapy  
	
 In previous chapters, I suggested the mechanisms that give CRISPR-Cas9 the potential to 
shift the ethics of gene therapy. In this chapter, I will combine and elaborate more on what I 
established in previous chapters to suggest that CRISPR-Cas9 gene editing may serve as a 
catalyst to shift regulations in gene therapy. To do so, I want to first summarize key points from 
previous chapters to serve as context: 
 Chapter one established the relationship between CRISPR-Cas9 and gene therapy. In this 
chapter, I talked about what CRISPR-Cas9 is from a technological standpoint and used this 
knowledge to better explain trends in its increasing efficacy to edit genes and its decreasing cost. 
In addition to this, I also postulated that these trends would ultimately lead to new ethical issues 
as a new era of molecular biology begins.  
  Chapter two established that the Declaration of Inuyama set forward regulations on gene 
therapy that were largely informed from utilitarian, Kantian, and liberal ethical frameworks. Said 
frameworks established that gene therapy should be limited to somatic cells and should not be 
used for enhancement purposes. Further, these decisions were largely framed on notions that the 
technology driving gene therapy was both unsafe and very expensive. 
Chapter three established the biopolitical drivers of CRISPR-Cas9 research through the 
concept of biopower as well how this technology can become normalized in society. I named 
these interacting forces the will and the means because they complement each other to push this 
technology across into society.  
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From the material I have provided above, it is evident that the ethical notions set forth by 
Inuyama are becoming increasingly obsolete with the advent of CRISPR-Cas9 gene editing 
technology via advances in both its accuracy and efficiency. Furthermore, when these aging 
ethics are met with biopolitical forces advocating for the increased use of gene editing on the 
human bios, the table is set for their shift. At the very heart of these developments is the 
disruption that CRISPR-Cas9 is causing in gene therapy. Because this disruption is so central to 
the issue, it is where I will begin my discussion of how this shift will occur.  
Before I begin to elaborate, first, I want to underscore that the regulations behind gene 
therapy are informed by its ethics. Because of this relationship, a shift in ethics will almost 
certainly result in a shift in its regulation. Hence, it could have a substantial impact not only on 
gene therapy, but on society. I will discuss more on this issue at the end of the chapter. 
CRISPR-Cas9 as a disruptor to gene therapy 
When gene therapy first began, it was limited to the delivery of nucleic acid polymers 
into a patient's cells. In turn, said polymers would be expressed as proteins or interfere with their 
expression (Ermak, G., 2015). This meant that gene therapy was very limited because it could 
only influence very specific disorders, oftentimes with little success. However, as I explained 
earlier with Kuhn’s “puzzle solving” framework, gene editing was already a part of the puzzle. 
Therefore, it is of no surprise that eventually the technology developed to allow this to occur (i.e. 
ZFN and TALENS). While these technologies did have moderate success, when most people 
think of gene editing, it is CRISPR-Cas9 that dominates conversation, even though both ZFN 
and TALENs have already shown moderate success in gene therapy. This is opposed to 
CRISPR-Cas9, which is only now (as of February 2017) beginning human trials.  
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When I say this, I am not speaking anecdotally. In the past few years the number of publications 
with relation to CRISPR-Cas9 and gene editing has greatly surpassed those of both ZFN and 
TALEN as is evidenced in the following figures.17 
 
 
It is evident from these figures that CRISPR research is currently dominating the field of 
gene editing. What’s more revealing is the almost quadratic shape of the curve for CRISPR 
which indicates an exponential growth in said research. This suggests that there is a lot of 
																																								 																				
17	Both	figures	are	published	by	Elsevier	with	data	obtained	through	December	10,	2016	from	SciVal	
https://www.elsevier.com/research-intelligence/campaigns/crispr	
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excitement about CRISPR within the gene editing community simply based on how fast research 
on CRISPR is growing. Clearly, the excitement behind CRISPR-Cas9 within the scientific 
community indicated that that there is something special to it. After all, to the outside observer, 
the fact that the largely unproven CRISPR-Cas9 is dominating its respective research field seems 
counter intuitive. So, what makes CRISPR-Cas9 so special? 
 As was discussed in chapter one, CRISPR-Cas9 is becoming increasingly cheap and 
effective when compared to previous technologies. Given this, CRISPR-Cas9 has the potential to 
overtake these more established technologies to become the king of gene therapy simply because 
of its economic value. Furthermore, since CRISPR-Cas9 is cheaper to use, it can be applied more 
broadly in gene therapy, which, when combined with its increasing accuracy, the quality of its 
edits should not be sacrificed.  
It is through this potential that CRISPR-Cas9 is creating a disruption in gene therapy 
because the attention that has resulted from the opportunities it presents as both a cheaper and 
safer means of gene editing is changing the landscape of biomedical research. For example, 
companies like Novartis, Johnson & Johnson and many other startups are beginning to use 
CRISPR-Cas9 to create new immunotherapies (Ally, 2016). The following graph illustrates the 
extent of which CRISPR-Cas9 is disrupting gene therapy, because assuming there are limits to 
funding, an increase in the amount of CRISPR publications is resulting in decrease of other 
similar areas of research.  
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From this graph18, it is evident that CRISPR-Cas9 is influencing the amount of research 
going into gene therapy. What is subtler, however, is that this is all done through gene editing as 
opposed to what is more considered more “traditional” gene therapy (i.e. delivering nucleic acid 
polymers). This only heightens the implications of a CRISPR-Cas9 disruption to gene therapy by 
revitalizing the field in unprecedented ways. Because of this “renaissance” of gene therapy, talks 
about its regulation are becoming more prevalent.  
This is where the Declaration of Inuyama becomes key because as mentioned in the last 
chapter, the first meeting to talk about regulating CRISPR-Cas9 in December 2015 essentially 
reaffirmed the regulations established by the Declaration of Inuyama. However, because 
CRISPR-Cas9 is disrupting gene therapy through tremendous increases in research, the 
technological advancements it is yielding are on pace to make the current restrictions in place 
obsolete.  
																																								 																				
18	CRISPR	info	graphic	published	by	Elsevier	with	data	obtained	through	December	10,	2016	with	data	from	SciVal	
https://www.elsevier.com/research-intelligence/campaigns/crispr	
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Revisiting the Declaration of Inuyama  
 What I mean by saying “obsolete” is that the premises by which the restrictions were 
developed no longer apply. Once this occurs, then new restrictions must be put in place to 
maintain order. This is where the biopolitical forces I talked about previously come into effect. 
Because there is both a will and a means to normalize CRISPR-Cas9 gene editing, there is a 
driving force advocating for the continued infringement upon the bios. Left unchecked, these 
forces can be very dangerous as they can lead to but not limited to enhancement, eugenics, and 
creating greater disparities between people/countries. The trick is to balance the restrictions to 
allow for more favorable outcomes while not suppressing the positive impact new developments 
to gene therapy can have. 
 To create this balance, we should look no further than Declaration of Inuyama. Even 
though times have changed and more recent conferences have taken place, the fact that these 
conferences essentially reaffirm the basic principles of Inuyama suggest that the prioritization of 
liberal, Kantian, and utilitarian ethical frameworks is still relevant. Hence, by looking at said 
priorities, it is possible to see how these frameworks can shift to continue being accepted while 
remaining appropriate to the technological advancements made possible by CRISPR-Cas9. 
 
Liberal Ethics: Enhancement  
 Liberal (Rawlsian) ethics were emphasized in the Declaration of Inuyama by maintaining 
that gene therapy could only be used to treat genetic illness and could not be used for 
enhancement purposes. While admittedly there are a lot of many nuanced issues at hand with 
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enhancement, one of the main backbones for this regulation has to do with the social impact 
enhancement it could cause.  This is because genetically manipulating anything other than an 
illness could lead to greater disparities in populations. If an individual could select specific traits, 
this could give them a competitive advantage over others in many regards such as physique, 
intelligence, or even lifespan (through telomere extensions).  Furthermore, while this thinking 
was already in place in the Declaration of Inuyama (refer to chapter two), the capabilities simply 
did not exist and thus this regulation seemed more as a precaution. This is no longer the case as 
CRISPR-Cas9 gene editing has successfully manipulated 62 genes at once. (Yang, et al., 2015) 
This currently places CRISPR in the range of being able to edit traits such as eye color which 
requires 16 genes (White & Rabago- Smith, 2010) and doesn’t this doesn’t even account for 
future innovations resulting in more genes being edited at once.  
Enhancement would certainly result in a disadvantage to those who abstain from gene 
editing for a variety of different reasons. What’s now different from when the Declaration of 
Inuyama was written is that if CRISPR-Cas9 makes enhancement affordable, there are still 
reasons people could choose not to undergo enhancement. Therefore, allowing for enhancement 
could detract from personal freedoms such religion, access, cultural and beliefs due to the 
competitive nature of society by forcing people to adapt to this competition. Thus, even if 
enhancement becomes affordable, it still violates the liberal principal of equality because people 
are not equally able to make these decisions. Therefore, if a shift in ethics were to occur, the 
restrictions on enhancement will likely remain in place based on ethical precedents. 
 What can change because of this increased affordability, however, is the scope of which 
gene therapy can be used. This is because work with CRISPR-cas9 has led to considerable 
progress in researching treatment options in non-genetic disorders such as HIV (Hu, W., et al., 
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2014) and organ donation (Yang, et al., 2015). If alternate uses for gene therapy such as this are 
made available, then new regulation would be likely be needed for a more interdisciplinary 
approach to treat such illness. This is because treatment for these disorders extends beyond just 
the genetic approach and requires more multifaceted interventions (i.e. social, surgical... etc.) 
which would require further regulation given new opportunities through gene therapy.  
 
Kantian and Utilitarian Ethics: Germline Manipulation 
The ban on germline manipulation by the Declaration of Inuyama is more complex in 
ethical terms.  On one side, the use of germline manipulation could spell the end for many 
terrible genetic diseases such as X-linked SCID, chronic lymphocytic leukemia, and Parkinson's 
disease. On the other is the potential devastation that could be inherited for generations if 
something goes wrong. The latter reasoning is why there is a ban on germline manipulation and 
is founded on Kantian ethics due to the moral obligation to treat all humans as an end.  
Moreover, Section VI of the Declaration of Inuyama19 makes it possible to continue 
ethical discussions on this issue. Thus, Kantian ethics also lays out the possibility for a shift in 
germline regulation to occur. As was discussed in chapter two, the safety of making such 
corrections is a major barrier. However, if the technology becomes safe, then human germline 
editing suddenly become an end. In this case, Kantian ethics would make it morally flawed not to 
allow patients undergo such a procedure due to the negative health effects a genetic malfunction 
has on them and future generations. 
																																								 																				
19	See	Appendix	A	
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The development of the eSpCas9 enzyme which has made CRISPR-Cas9 much more 
accurate, in addition to the possibility of increasing this accuracy overtime may eventually 
resolve this issue by making germline editing safe. This safety is complemented by an increased 
understanding of the genetic basis of disease. Interestingly, CRISPR-Cas9 is getting to a point 
where it can become limited by the amount of genomic information available and thus both gene 
editing and genomics will need to work together to increase the safety of germline manipulation. 
With this combination, it can eventually be possible to treat germline editing as an end which per 
Kantian ethics should result in its adoption into the gene editing paradigm.  
Evidence of this is already beginning to occur. In 2015, the UK ruled for the NHS 
backing of tri-parental embryos. While not technically editing a gene per se, this procedure 
introduces the DNA of both parents into a donor egg with healthy mitochondrial RNA (mRNA). 
In doing so, a potential cure for mitochondrial diseases is in place by replacing defective mRNA 
(Mitalipov, S., & Wolf, D., 2014). This sets up an important precedent for the use of germline 
gene editing since the technique is already being used and helping improve quality of life. More 
importantly, however, on Valentine’s day of 2017, the National Academies of Sciences, 
Engineering, and Medicine recommended that germ-line modification be permitted in the 
future20. This, however, does not allow for germline modification just yet. Rather it 
acknowledges that there is a potential in certain narrow circumstances to prevent the birth of 
children with serious diseases using this technology.  
These events suggest that if CRISPR-Cas9 can work effectively and safely, then it could 
become more “morally correct” to use these techniques to save lives.  Thus, the Kantian 
																																								 																				
20	The	report	is	available	online	at	the	National	Academies	of	Science,	Engineering	and	Medicine	website	and	is	
free	to	download	(https://www.nap.edu/download/24623)		
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framework of germline regulation may certainly shift regulations to afford the possibility of 
future germline modification.    
 Furthermore, it is not enough to suggest that the increased safety of germline 
modification is enough to solely drive this shift. After all, if there are more viable alternatives 
such as IVF and genetic screening to germline manipulation, then the cost of using it is greater 
than its benefit. While there is no clear-cut answer to which technique has more utility, with a 
CRISPR-Cas9 disruption, the utility of alternate techniques could be reduced. This is a result of 
both a reduction in price and the fact that germline manipulation would reduce the need for their 
use by stopping genetic illness at its source. 
 Additionally, the utilitarian ethical framework laid out in the Declaration of Inuyama 
suggested a ban on germline manipulation research. However, because CRISPR-Cas9 did not 
develop solely for germline manipulation and it is rather a byproduct of its ability to edit genes, 
its use bypasses this principle once the technology becomes more accurate through other avenues 
of research. Hence, the benefits may override the costs of developing germline manipulation 
techniques with CRISPR-Cas9. Once again, this would lead to a shift in ethical priorities because 
it is becoming more efficient to invest these resources in germline manipulation since it gets to 
the route of the problem as opposed to using resources on a case by case basis.  
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Why we should care? 
The ethical issues regarding gene therapy are undeniably complex. They require finding 
the right balance between what is a cost to society versus its potential benefits due to the 
subjectivity of prioritizing different ethical frameworks. Whereas currently these issues pertain 
primarily to germline gene editing as well as the limits to the medicinal application of gene 
editing, the disruption caused by CRISPR-Cas9 in gene therapy can cause regulations to change.  
Change can be scary. Yet, by focusing on how gene therapy can change from an ethical 
perspective, it has become apparent that this change should not be scary and can even be 
exciting.  
After all, an ethical shift is not inherently good nor bad, since ethics are simply 
established societal standards. Therefore, any change represents what society finds suitable. That 
being said, such changes allow for a more appropriate response given our increased knowledge 
and capabilities made possible by CRISPR-Cas9. Additionally, because biopower serves as a 
constant force pushing for the increased use of CRISPR-Cas9 in the bios of humans, there is a 
likelihood that this push can again further shift ethics of gene therapy. This push is what fuels the 
Gattaca-like dystopian scenarios such as designer babies or species-specific bioweapons.  
Nevertheless, even if CRISPR-Cas9 is eventually able to fulfill our gene editing dreams, 
ultimately we are the ones in charge. We are the ones who have the privilege to decide how gene 
editing technologies can shape our future. Therefore, there is a particular weight placed on those 
who create these regulations, making it imperative that they represent the best interests of 
society.  
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Appendix A 
  
                                          THE DECLARATION OF INUYAMA 
 
                     Human Genome Mapping, Genetic Screening and Gene Therapy 
 
I.  Discussion of human genetics is dominated today by the efforts now under way 
on an international basis to map and sequence the human genome. Such attention 
is warranted by the scale of the undertaking and its expected contribution to 
knowledge about human biology and disease. At the same time, the nature of the 
undertaking, concerned as it is with the basic elements of life, and the potential for 
abuse of the new knowledge which the project will generate, are giving rise to 
anxiety. The Conference agrees that efforts to map the human genome present no 
inherent ethical problems but are eminently worthwhile, especially as the 
knowledge revealed will be universally applicable to benefit human health. In 
terms of ethics and human values, what must be assured are that the manner in 
which gene mapping efforts are implemented adheres to ethical standards of 
research and that the knowledge gained will be used appropriately, particularly in 
genetic screening and gene therapy. 
 
II.  Public concern about the growth of genetic knowledge stems in part from the 
misconception that while the knowledge reveals an essential aspect of humanness 
it also diminishes human beings by reducing them to mere base pairs of 
deoxyribonucleic acid (DNA). This misconception can be corrected by education 
of the public and open discussion, which should reassure the public that plans for 
the medical use of genetic findings and techniques will be made openly and 
responsibly. 
 
III.  Some types of genetic testing or treatment not yet in prospect could raise 
novel issues - for example, whether limits should be placed on DNA alterations in 
human germ cells, because such changes would affect future generations, whose 
consent cannot be obtained and whose best interests would be difficult to 
calculate. The Conference concludes, however, that for the most part present 
genetic research and services do not raise unique or even novel issues, although 
their connection to private matters such as reproduction and personal health and 
life prospects, and the rapidity of advances in genetic knowledge and technology, 
accentuate the need for ethical sensitivity in policy-making. 
 
IV.  It is primarily in regard to genetic testing that the human genome project gives 
rise to concern about ethics and human values. The identification, cloning and 
sequencing of new genes without first needing to know their protein products 
greatly expand the possible scope for screening and diagnostic tests. The central 
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objective of genetic screening and diagnosis should always be to safeguard the 
welfare of the person tested: test results must always be protected against 
unconsented disclosure, confidentiality must be ensured at all costs, and adequate 
counselling must be provided. Physicians and others who counsel should 
endeavour to ensure that all those concerned understand the difference between 
being the carrier of a defective gene and having the corresponding genetic disease. 
In autosomal recessive conditions, the health of carriers (heterozygotes) is usually 
not affected by their having a single copy of the disease gene; in dominant 
disorders, what is of concern is the manifestation of the disease, not the mere 
presence of the defective gene, especially when years may elapse between the 
results of a genetic test and the manifestation of the disease. 
 
V.  The genome project will produce knowledge of relevance to human gene 
therapy, which will very soon be clinically applicable to a few rare but very 
burdensome recessive disorders. Alterations in somatic cells, which will affect 
only the DNA of the treated individual, should be evaluated like other innovative 
therapies. Particular attention by independent ethical review committees is 
necessary, especially when gene therapy involves children, as it will for many of 
the disorders in question. Interventions should be limited to conditions that cause 
significant disability and not employed merely to enhance or suppress cosmetic, 
behavioural or cognitive characteristics unrelated to any recognized human 
disease. 
 
VI.  The modification of human germ cells for therapeutic or preventive purposes 
would be technically much more difficult than that of somatic cells and is not at 
present in prospect. Such therapy might, however, be the only means of treating 
certain conditions, so continued discussion of both its technical and its ethical 
aspects is essential. Before germ-line therapy is undertaken, its safety must be very 
well established, for changes in germ cells would affect the descendants of 
patients. 
 
VII.  Genetic researchers and therapists have a strong responsibility to ensure that 
the techniques they develop are used ethically. By insisting on truly voluntary 
programmes designed to benefit directly those involved, they can ensure that no 
precedents are set for eugenic programmes or other misuse of the techniques by 
the State or by private parties. One means of ensuring the setting and observance 
of ethical standards is continuous multidisciplinary and transcultural dialogue. 
 
VIII. The needs of developing countries should receive special attention, to ensure 
that they obtain their due share of the benefits that ensue from the human genome 
project. In particular, methods and techniques of testing and therapy that are 
affordable and easily accessible to the populations of such countries should be 
developed and disseminated whenever possible. 
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